Allergy Therapeutics (FRA:HHU) EPS (Basic): €-0.01 (TTM As of Dec. 2025)


FRA:HHU Allergy Therapeutics PLC FRA:HHU
39 GF Score
Price €0.07
GF Value €0.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Allergy Therapeutics EPS (Basic)?

Allergy Therapeutics FRA:HHU -3.97% 39 EPS (Basic) is €-0.01 as of Dec. 2025. GuruFocus rates FRA:HHU with a GF Score™ of 39/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Allergy Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.01.

Allergy Therapeutics's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.01.

Allergy Therapeutics's EPS without NRI for the six months ended in Dec. 2025 was €-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 27.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Allergy Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 66.90% per year. The lowest was -93.90% per year. And the median was 3.55% per year.

Allergy Therapeutics  (FRA:HHU) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Allergy Therapeutics EPS (Basic) Related Terms

Allergy Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics EPS (Basic) Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.03 -0.08 -0.01 -0.01

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.00 -0.01 -0.00
FRA:HHU
39GF Score
Allergy Therapeutics PLC FRA:HHU
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allergy Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Allergy Therapeutics's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-47.211-0)/4766.440
=-0.01

Allergy Therapeutics's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-22.771-0)/5224.773
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.01 mean?
Allergy Therapeutics (FRA:HHU) has a EPS (Basic) of €-0.01 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' EPS (Basic) too high?
Allergy Therapeutics' current EPS (Basic) is €-0.01. Overall, Allergy Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' EPS (Basic) compare to ZTS and UTHR?
Allergy Therapeutics' EPS (Basic) of €-0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Allergy Therapeutics and its competitors. Allergy Therapeutics's current EPS (Basic) is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (FRA:HHU) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.07 — trading 141.7% above its estimated fair value. The current EPS (Basic) is €-0.01. Allergy Therapeutics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Allergy Therapeutics (FRA:HHU), the current EPS (Basic) is €-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allergy Therapeutics (FRA:HHU) Overvalued in 2026?

Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued. The current stock price of €0.07 is trading 141.7% above its estimated GF Value™ of €0.03. GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HHU:

  • EPS (Basic): €-0.01
  • GF Value™: €0.03 vs. price of €0.07 (141.7% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the FRA:HHU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAAGY:UKHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
39GF Score

Get the complete analysis for FRA:HHU

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.03
GF Value